Eisai's Leqembi launch tripped up on a host of challenges
https://www.fiercepharma.com/market...picture-alzheimers-drug-trips-host-challenges
It wasn’t supposed to be like this: Eisai and Biogen’s new Alzheimer’s disease drug Leqembi was supposed to be the chosen one after the flop that was Biogen and Eisai’s Aduhelm, but neurologists are voicing “frustration” at core elements of the therapy’s rollout.
That’s according to a stark new report out by life sciences consultants at Spherix that delved down into insights from 75 high-prescribing U.S. neurologists that work with Alzheimer’s patients.
The picture painted by them is bleak: Now around six months after the launch of Leqembi, “few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments,” Spherix’s analysis found.
It also found that satisfaction with Leqembi “is relatively low,” with the average satisfaction rating being a full 15% lower than the typical rating for a new neurology market entrant, the consultants said.
“Perhaps related to that, less than half of neurologists surveyed are actively recommending Leqembi to patients,” the report found.
https://www.fiercepharma.com/market...picture-alzheimers-drug-trips-host-challenges
It wasn’t supposed to be like this: Eisai and Biogen’s new Alzheimer’s disease drug Leqembi was supposed to be the chosen one after the flop that was Biogen and Eisai’s Aduhelm, but neurologists are voicing “frustration” at core elements of the therapy’s rollout.
That’s according to a stark new report out by life sciences consultants at Spherix that delved down into insights from 75 high-prescribing U.S. neurologists that work with Alzheimer’s patients.
The picture painted by them is bleak: Now around six months after the launch of Leqembi, “few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments,” Spherix’s analysis found.
It also found that satisfaction with Leqembi “is relatively low,” with the average satisfaction rating being a full 15% lower than the typical rating for a new neurology market entrant, the consultants said.
“Perhaps related to that, less than half of neurologists surveyed are actively recommending Leqembi to patients,” the report found.